An Open-Label, Randomized, 2-Period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects

Trial Profile

An Open-Label, Randomized, 2-Period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Bosutinib (Primary) ; Bosutinib (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Results assessing absolute bioavailability presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 30 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov .
    • 10 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top